Lantern Pharma
LTRN
26 hedge funds and large institutions have $8.06M invested in Lantern Pharma in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.38% less ownership
Funds ownership: 13.48% → 13.1% (-0.38%)
22% less capital invested
Capital invested by funds: $10.4M → $8.06M (-$2.32M)
94% less call options, than puts
Call options by funds: $1K | Put options by funds: $17K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$68K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$67.6K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
+$16.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.11K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$145K |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$109K |
| 3 |
Morgan Stanley
New York
|
-$68.6K |
| 4 |
WWM
Wolff Wiese Magana
Carslbad,
California
|
-$27.3K |
| 5 |
JP Morgan Chase
New York
|
-$25.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$6.91K | -1,158 | -90% |
|
|
27
Two Sigma Investments
New York
| – | -$145K | -20,322 | Closed |
|
LTRN Hedge Fund Activity: Q2 2022 in Review
26 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2022, worth a combined $8.06M — down 22% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LTRN positions and 1 closed out — a net gain of 1 holder — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $68K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $145K sold.
- 26 institutional investors held Lantern Pharma (LTRN) as of Q2 2022, up from 25 in Q1 2022.
- Funds reported $8.06M of Lantern Pharma stock for Q2 2022, down 22% quarter-over-quarter.
- 2 funds opened new Lantern Pharma positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest Lantern Pharma buyer in Q2 2022 was Renaissance Technologies, an estimated $68K added.
- The largest Lantern Pharma seller in Q2 2022 was Two Sigma Investments, an estimated $145K sold.
Based on aggregated 13F filings for Q2 2022.